PNP Therapeutics Names Claude Bennett and James Fuqua to Board of Directors Business Wire BIRMINGHAM, Ala. -- July 2, 2013 PNP Therapeutics, Inc.—an early-stage Birmingham-based biopharmaceutical company created from research conducted at Southern Research Institute and The University of Alabama at Birmingham (UAB)—today announced that Dr. J. Claude Bennett and Mr. James F. Fuqua have joined its Board of Directors. “We are honored to have these local leaders, with their very strong life sciences management backgrounds, join the PNP Therapeutics Board of Directors,” said John C. Lankford, Ph.D., president of Phase I Holdings, LLC and chairman of the PNP Board. “Their expertise is especially beneficial and timely now that PNP’s technology is in Phase 1 clinical trials for solid tumors.” In 1997, Dr. Bennett was designated by the University Board of Trustees as Distinguished University Professor Emeritus. He served as President and Chief Operating Officer of BioCryst Pharmaceuticals, Inc. from 1997-2009. Prior to assuming this position, he served as President of the University of Alabama at Birmingham (UAB). He joined the faculty of the UAB faculty in 1965, where he served as Chairman of the Department of Microbiology, Director of the Division of Clinical Immunology and Rheumatology, and Director of the Multipurpose Arthritis Center. Dr. Bennett received his undergraduate degree from Samford University in Birmingham in 1954 and his medical degree from Harvard Medical School in 1958. He completed fellowships at the Massachusetts General Hospital, NIH, and the California Institute of Technology. His work has appeared in more than 200 scholarly journals and publications, and he has served as President of the American College of Rheumatology, President of the Association of American Physicians, Chairman of the Health Sciences Policy Board of the Institute of Medicine, and Editor of Cecil Textbook of Medicine. Mr. Fuqua has demonstrated top level performance in multi-national and small corporate strategies, business development, senior sales management and health science organizations. He is currently Senior Consultant for The Center for Leadership Studies/Performance Impact, Inc. Prior to that he was Vice President, Strategic and Business Development for CE Outcomes, LLC and held several senior management positions with Merck and Co. from 1979-2010. He received a Bachelor of Science degree in Biology with minors in Chemistry and Physics from Vanderbilt University in 1976. ABOUT PNP THERAPEUTICS PNP Therapeutics^®, Inc. is an early-stage, biopharmaceutical company engaged in the development of a platform technology and proprietary products for the treatment of cancer. The technology is currently in Phase 1 clinical trials. PNP is the exclusive licensee of a comprehensive collection of patents that broadly and specifically cover the Company's technology. These patents are owned jointly by the University of Alabama at Birmingham (UAB) Research Foundation and Southern Research Institute. Persons interested in learning more about the PNP Therapeutics clinical trial can access the information at www.ClinicalTrials.gov or contact Dr. Nancy Gray at firstname.lastname@example.org or by phone at 205-581-2922. Contact: For PNP Therapeutics Rhonda Jung, 205-337-9634 Jung@SouthernResearch.org
PNP Therapeutics Names Claude Bennett and James Fuqua to Board of Directors
Press spacebar to pause and continue. Press esc to stop.